(177)Lu-PSMA radioligand therapy for prostate cancer

(177)Lu-PSMA radioligand therapy (RLT) using inhibitors of the prostate-specific membrane antigen (PSMA) is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer (mCRPC). Current literature suggests that this therapy is well tolerated and effective. Based on clinical need and current evidence it is implemented in a growing number of centers worldwide. Here we review important aspects of (177)Lu-PSMA RLT, including patient stratification, therapy protocol, concomitant medication and follow-up to inform medical staff involved in RLT and care of mCRPC patients.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Jun 29 [Epub ahead of print]

Wolfgang Peter Fendler, Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, Matthias Eiber

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angel, Germany., Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany., Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe